Press releaseBusiness Wire
Oncternal Therapeutics
ONCT · NASDAQ
$0.5266−$0.1673 (−24.11%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releaseGlobe Newswire
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
- Press releaseBusiness Wire
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
- NewsAvi Kapoor
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
- NewsAvi Kapoor
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Surges Over 100 Points; ModivCare Shares Plummet
- NewsAvi Kapoor
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
- NewsAvi Kapoor
US Stocks Mixed; Producer Prices Increase In August
- Press releaseGlobe Newswire
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
- Press releaseGlobe Newswire
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.